right pfizer and plow there you are joining forces to partner is seeing eye to eye that. yes they have to see eye to eye to make it work you know we've seen so many mergers and bringing together of units in the past where when you get down to the great of the every day important decisions that are important to executives but also to the normal workers where there are differences differences and cultures and interests and then the thing goes sour so they have to work together but investors thinking this is a great idea the shares are going up pfizer not quite as much as glaxo smith kline but clark so smith kline advancing by around six percent at the moment really how is this going to shake up the pharmaceuticals market. well. together they will be world number one in these o.t.c. consumer oriented health products with a market share of seven point three percent way more than for example buyer or johnson and johnson or sanofi who are at about four percent but remember that part of the driver of this merger is the pressure that the market has but on the brand name producers

that was the key for pfizer because three years from now whenever it is, pfizer is not going to sell at 32% they'll sell over time or get their values >> are you surprise how much values of these drug companies they spin and a lot of these companies spin off medical devices. j&j, they have so much if they want to spin off i know we got to go. david, this is some warning. we are literally just getting started. >> we are just getting started on the hills of our conversations and all eyes will be on us when we come back talking about facebook, wall to wall, facebook is back on defense. not like the knicks, they don't get back on defense. >> the new york times reports, let's take a look at the futures, we'll get start with trading in 14 minutes now. we got a lot more from "squawk on the street" after this. at fidelity, our online u.s. equity trades are just $4.95. so no matter what you trade, or where you trade, you'll only pay $4.95. fidelity. open an account today. you'll only pay $4.95. this is moving day with the best in-home wifi experience and millions of wifi hotspots to help you

gsk will have a 68% stake and pfizer 32%. glaxosmithkline's chief executive emma walmsley will chair the newjoint venture. we'll have more on that with out business editor in just a few minutes. british businesses have criticised politicians for focusing on in—fighting, rather than preparing for brexit, warning that there's insufficient time to get ready for a no—deal scenario. with 100 days to go before the uk leaves the eu, business groups say they've been watching in horror the ongoing rows in westminster. they say the idea that no—deal can be managed is not credible. billionaire entrepreneur elon musk has unveiled a prototype tunnel in los angeles, designed to transport cars at high speed around the city. it's only 1.5km long so far, but the goal is a network of tunnels to alleviate chronic traffic congestion. the project is being developed by mr musk‘s construction outfit, called the boring company. anything but! the mobile unit of the japanese tech company softbank, a bit of a damp squib. it floated in tokyo but

a new pharmaceutical giant in the making glaxo smith kline and pfizer announced a joint venture that will create the biggest over the counter drug supply and. also coming up the vision of how you will someday ride in one of his tesla electric cars has just taken one more step closer towards reality. welcome to the business so pharmaceutical giant pfizer add to glaxo smith kline a forging an alliance that will be worth billions to pharma companies plan on joining their over the counter prada. division's last year they had a combined turn over of almost thirteen billion dollars pfizer will hold on to thirty two percent of the plan to joint venture glaxo to sixty eight percent the next step will be to flow to the new company on the stock exchange. that's going out to frankfurt to our man there will be buds and ask him what this news means for the world's huge health care market and in particular for the two pharma giants. yes and i think glaxo smith kline is also finally seeing eye to eye with investors heavyweight investors that have been putting pressure on glaxo smith kline g s k let

shares now looking at glaxo up 7% pfizer up about 1.5% pfizer has been trying to sell that consumer business for quite some time. couldn't find a taker. >>> in other corporate news, ge has filed for -- ge would not specifically confirm the filing but points out it announced in june to separate the business. that stock now up about 3% >>> general mills out with earnings reporting 85 cents a share beating estimates by 4 cents revenue did miss forecasts, however, and organic sales fell by 1%. >>> and then mortgage applications tumbled by 5.8% last week. according to new figures from the bankers association. refinancing activity fell. the average 30-year mortgage rate was down by two points during the week to 4.94% ken, back to the ge story quickly. ipo spinoff of the health care unit what does that do in terms of raising cash potentially for the company or giving it back to shareholders >> it sets health care on some course look ge unfortunately is a disaster that's the only way you can describe it. a disaster it's a monumental example of bad governance and horrible leadership you look at virtu

pfizer was lower and glaks o was higher. fran holland with the details. >> makers of advil and kped rein creating a merger creating the biggest consumer health company in the world. they announced the deal on wednesday. they generate ane com $2.7 billion in revenue a year. >> we announce a deal strengthens to you two businesses and creores value shareholders. >> this will sell somee of best known brands. glaks o will own 68%. pfizer the the they say this merger will make the company the industry leader with7% of the overall global market. >> the new consumer business is going to have suchignificant scale we will be number one in pain relief, number oir in reory, number one in vitamins,inerals and supplements, leader in over-the-counter skin health and top one or two player in 10 1 o thbigds markets in the world, including by the way, the u.s. >> the ceo of glaks o smith klein, ema whamsly emphasized the b uked drug maker to fund and focus on drug research. >> it allows us to strengthen on theumber one priority of pharma pipe

tightening in policy through 2019 >> gsk jumps to the top of the stock 600 as the pharma giant teams up with pfizer to combine their consumer health units into a joint venture with sales of nearly ten billion pounds. >> italian banks are set for the best day in three weeks after the government strikes a budget deal with the eu avoiding sanctions on spending plan and bringing an end to months of uncertainty. >> austrian oil and gas company muscles in on a long term strategic contract with adnoc to develop ultra sour gas in the persian gulf catch our interview with rainer seele in half an hour. >>> all right. good morning, everybody. welcome to "street signs." it's december 19th you would think is -- we're edging towards the end of the year and things would calm down. of course, it is fed day all eyes on the fed decision this isn't usually contentious today is setting up to be a contentious meeting because despite mounting opposition, the fed is expected to raise rates by a quarter point later today it will be the fourth hike this year the central bank looks to normalize policy by winding down the mu

it is questionable whether the dossier should have been referenced or transmitted to the pfizer court it is questionable why the justice department did not more specifically identify the origins of the dossier. and those four judges at some point did not press the justice department for more information where it got this information. but we ought not to lose sight of the very fundamental question which is far broader and more fundamental than fisa. so how does joe sixpack know whether the fbi investigation is legitimate? or conducted for political or personal how do they make that judgment? let me just say a little homework assignment sit down over the weekend with google and try to figure out an answer to this question. when can the fbi investigate me? what you will find there is a launch of a little statue here a little statute there lots of executive orders, five times from the attorney general but there is no charter for the fbi. there is no statute that says in simple straightforward comprehensive terms, what the authority of the fbi is. what can it do cracks how can it do it? wh

have 68%.oing to pfizer will have 32%. laxo,: g 's coming through confirming 80 pence per share in 2018. it remains committed to the current dividend policy. manus: what does the market get back in return? what pfizer and glaxo are saying is it is about synergies. a billion pounds, and cash costs of 9 billion. 2022.ope to save 0.5 by and non-cash charges of 0.3 billion. coming up, with 100 days until brexit, the u.k. troops.puts 3500 when you're traveling to work, tune into bloomberg radio live on your mobile device or digital radio in the london area. this is bloomberg. ♪ manus: 41 minutes until the start of cash trading today. nejra: this is "bloomberg daybreak: europe." i am nejra cehic. manus: i am manus cranny. let's look at the markets, asian stocks are in the green. talks will happen in january, that is what we are hearing from the mnuchin. asia, 16% of the global market less than the u.s. u.s. futures are back to flat. crude wiped out over two sessions, down 9%. people are questioning global growth and the cuts f

it has a nice way of incorporating the assets of pfizer it could not afford to buy and bolstering its formal research division, giving it a continuing kick in financial performance. we will play you some tape from the cfo. sitick look at where we with the italian bond market story. this is the picture as you can see, hire for italian bcp's. that move throughout the day. a little higher in terms of yields. will the parliament passed this budget? vonnie: we typically see movement of 1% on fed day, fomc decision day. 1%, and500 up 9/10 of there are very few stocks in the dow that our loader. general electric which received an upgrade, general mills and some energy companies rebounding. that might be waiting on the dollar, the dollar index is weaker. you don't normally see such dollar trading and of course, brexit. weighing potentially on the dollar with a little bounce in some of those currencies. then there is the rate question. let's get to taylor riggs. taylor: we are prepared to hear from the federal reserve around 2:00 p.m. or so. interesting,ery putting off this support level of ab

be big if we talk about a systemic problem than possibly we could go back to pfizer itself but again this is what i find interesting that with mister chief it's a book i had to go through the index there is no mention of pfizer or surveillance or mister putin or election interference which i thought was interesting because that was at the heart of this but we know from pfizer declarations that were made public that for years and essay was engaged going after multiple communications i will go page by page and then to have that handle and i agree with you. and then surveillance it is extremely important with those possibilities are and that there is no necessary connections into surveillance thoset muslim american communities and the next time whether or not there was reason to believe to improperly wiretap tresidential for his campaign and the fact with the war on terror it is very dangerous to say at the behest of the obama administration in this attack with the tromp campaign. and one of the things that we know is the enormous member of fact what the fbi did and did not do we have t

i fade pfizer. not alitteration a company that did nothing for four years and rerated 46% the last six months is reralted valuationwise. it's as simple as that great company and balance sheet. i understand why they did this it's already rerated fade it. >> let's settle with the score with "options action" and look who makes a special appearance today. i believe it's in honor of guy's birthday dan nathan we are discussing pfizer as you heard. what is the options market telling but whether to trade or fade. >> on a downday for the stock and space getting roughed up, call volume is two times that of puts in phaser i'm trading this this is interesting near-term. obviously fwlaes been optimism about drugs, valuation support, kind of defensive in this space. but today there was a trade just short-term in pfizer where traders were buying the december 28th weekly 44 calls paying 30 cents for those. the larges largest block of those, 5,000 traded on the day this is a short-term play to goat to the upper end

glaxosmithkline announced a "pfizer combining consumer health care pricing. and we talked to the ceo of smithkline earlier today who explained the driving force was about getting the capital they needed to invest in prescription drug businesses. >> it also allowed us to strengthen the pharma and vaccine businesses because in the midterm we have seen significantly larger cash flows from this big joint venture to continue to fund our number one priority, strength in the pipeline. david: the slower growing business is the consumer business, but the bigger risk is what they are grouping the capital into. lisa: we will definitely be watching that. i'm looking at ipo's, we saw raised $23.6 billion in initial public offerings and it didn't go so hot in its first down atrading, riding lot of other japanese companies. blue apron, though, putting it out of its league. blue apron ipo has launched more than 90%, the third worst ipo ever. which is like, what's the first? bet it's like pets.com. lisa: i'm in my goodness. have you use them? david: i haven't, but remember th

pharmaceutical giant pfizer and glaxo smith kline are forging an alliance that will be worth billions to pharma companies plan on joining their over the counter product divisions last year they had a combined turnover of almost thirteen billion dollars pfizer will hold on to thirty two percent of the planned joint venture glaxo will keep sixty eight is the next step will be to float the new company on the stock exchange. a little earlier i spoke to our markets correspondent only bots in frankfurt and i asked him if the two partners are actually seeing eye eye to. yes and they have to see it to make it work you know we've seen so many mergers and bringing together of units in the past where when you get down to the nitty gritty of the every day important decisions that are important to executives but also to the normal workers where there are differences differences in culture is an interest and then the thing goes sour so they have to work together but investors thinking this is a great idea the shares are going up pfizer not quite as much as glaxo smith kline but quite so smith kline

pfizer, big news today. >> an exciting story. axo you have the nicotine chewing gum, the chapstick lip balm will be put under ruone roof. it will be a separate unit on the london stock exchange. glaxo has had a difficult couple of weeks. synergies can save half a billion, it is positive. absolutely huge story. that could spread to other names in the industry. watch the drugmakers. we think it is trending lower this morning, they took a hit in the fourth quarter. this comes from their asia unit. it is the first investment bank the reports the volatility that hits the continent. stock markets likely to come under pressure. us.: thank you for joining you can get the latest stock stories from our equities team at first go on your bloomberg. the open is right after this break. this is bloomberg. ♪ anna: less than a minute away from the start of equities trading. the euro is a little stronger this morning. 3/10 of 1%. generally, it is the dollar weakness we are seeing. many in the market are expecting that the pricing suggests the ma

glaxosmithkline is forming a in you venture with pfizer. they're splitting into two businesses, the consumer versus the pharmaceutical and putting them together and eventually spin it off. glaxo ceo will join us first on cnbc. >>> japan's biggest ever ipo was a flop the stock fell 14% it's wednesday, december 19th. and we'll get close, aren't we 2018 "squawk box" begins right now. ♪ and it's all right and it's coming home ♪ ♪ we have to get right back to where we started from ♪ ♪ love is good >> live from new york where business never sleeps, this is "squawk box. >> good morning, everybody welcome to "squawk box" on cnbc. we are live from the nasdaq market site in times square. i'm becky quick. let's take a look at the u.s. equity futures at this hour. yesterday we saw strong moves in the morning. but that all fizzled through the afternoon. you had all three major averages briefly falling into the red before you did get a late day push for stocks that left us with some modest advances. dow was up by 82 points yesterday. the nasdaq

he files for the pfizer after this thing has been widely debunked. and how does he seem to avoid all of this? he is a central figure in this entire scandal. >> he governs of rod rosenstein and others involved in this and it's very specific. it says, if you have a personal or political involvement in a case or with somebody else involved in the case, you must disqualify yourself. it's not, may be, or g.i. might, it's mandatory. rosenstein has ignored the relations in the code of professional responsibility with impunity. this is a guy that has been interviewed by robert mueller the special counsel as a key witness in the case and yet, rosenstein presides over the case? this is the ultimate conflict of interest and that, instead of accusing william barr or matt whitaker of a conflict of interest, let's all take a look at rod rosenstein. he should have been kicked off of this case from the beginning. >> dan: it's amazing that everyone wants recusal's except for rosenstein. after the break, one democratic congressman had a christmas themed meltdown on ca

plus, big pharma getting a big shakeup as glaxosmithkline and pfizer strike a deal. let's get you started with a quick check of the major averages. u.s. stocks gaining ground as investors race for a dovish rate hike from the fed. dow and nasdaq gaining for the second session. energy and materials leading the gains. treasuries in a holding pattern, pushing towards 2.8%, which has been a strong support level. we have seen growth concerns, trade tensions weighing on yields. amanda: while we're getting a little bounce back for energy stocks in the price of crude, i want to show you a longer-term her crude has been an energy stocks in the s&p 500 relative to the index. that is the blue line. as crude prices go back to multi-decade lows, we see a real breach of recent prices. 500 ratio ishe s&p also in a steep decline, going back to previously sharply low levels. a little bit of context of her the prize has been and of a brake for energy versus the s&p 500. shery: one thing we need to keep an eye on is a potential government shutdown in the u.s. on friday. we hear the sena

administration used the authority and the capability of the state for illegal and release it on - - illicit pfizer warrants to use the fbi to infiltrate the trunk campaign for the purposes to plant so russian collusion. it is also a diversion from the largest treasonous financial scandal in american history that would be the crime of uranium one. the people are looking for russian collusion they merely need to look at bill and hillary clinton and their acceptance of $145 million from the russian energy company while the transfer of 20 percent of america's enriched uranium was on hillary's disk on - - desk for transfer to the russians. now few americans i think could withstand the legal examination that i have been under for the last two and half years. i now know as "the new york times" reported on januar januah , 2017, long before the appointment of mueller as the special counsel that i was among three advisors to trumpet the candidate under surveillance under the previous administration. probable cause? no. this has been two and a half years of hell. not only was i under surveillance in 2016 but

with our financial markets a correspondent orly bods is standing by for us in frankfurt so what he pfizer and galax of smith kline joining forces are we talk about two partners seeing eye to eye here. yes and i think glaxo smith kline is also finally seeing eye to eye with investors heavyweight investors that have been putting pressure on glaxo smith kline g s k let's term it for short to get more out of the company to deal unveil the hidden value in the company and do a spinoff like this and now it's doing it t.s.k. is obviously the more a weighty partner in this but both stand to gain if they can actually make good on the cost cutting and the purchasing price advantages that they are hoping to get from this union in the consumer health care business all right and how is this this joint venture going to shake up the pharmaceuticals market. well they both will be clearly now number one together in the consumer health business among brand names at least seven point three percent of post will be their market share compare that to four percent for the other leading contenders like bayer for

if you look at this chart you can see that pfizer traced out a left shoulder as it rallied through the month of october then started declining aggressively in november it formed the head and then december caught a rally and then a pull back to create the right shoulder the key with this pattern is the neckline the line that connects the head to the two shoulders when a stock breaks out above that line it tells the technician you're about to witness a big move pfizer's neckline was a $25.80 and collins predicted if you take out the neckline it could be in for a monster run. given that money was pouring out of the staples and drug stocks headed for the industrials i was confounded by the bullish reverse head and shoulders pattern i. didn't trust it one bit. i mean, come on, i knew it was a bad stock. but collins said rotations smoked agencies. you had to close your eyes and buy the stock because something big was going on i didn't think it was inconceivable. sure enough, he was right. i was wrong. the stock almost instantly jumped more than 10% after collins told me to buy it with both h

pharmaceutical giants pfizer and glaxo smith kline forging an alliance that will be worth billions the two pharma companies plan on joining their over the counter products to vision's last year they had a combined turnover of almost thirteen billion dollars pfizer will hold on to thirty two percent of the plant's joint venture luxo to sixty eight percent the next step then will be to flow to the new company on the stock exchange. another few things are more frustrating than being stuck in traffic especially when you are on the way to an important appointment and most of us just complain about it and get on with our lives well tech entrepreneur the long musk started digging and the result of his endeavors has just been unveiled. electric cars whizzing autonomous lee underground this is ilan musk the lucian to what he once called soul destroying traffic in los angeles now with the unveiling of a three kilometer tunnel and whole flooring just outside l.a. his vision is a step closer to reality so you can have as many channels as you want and i'm pretty sure everyone in the united states i

and pfizer were up sharply in london and u.s. exchanges by more than seven and fourteen percent respectively on that. and the latest figures from the u.s. department of housing and urban development or hud indicate that homelessness has increased for the second year in a row hud's latest report estimates the u.s. homeless population at five hundred thirty three thousand in january twenty eighth seen with two thirds of those people lacking any form of shelter while the increase was small the trend seems to belie you low u.s. unemployment statistics new york city and los angeles account for twenty five percent of the u.s. homeless population but seattle's notably rose to twelve thousand reflecting the trend of rapidly rising weapons and booming west coast cities in global perspective hong kong officially showed a twenty two percent home increase in homelessness for twenty seventeen to twenty eighteen in the u.k. the office of national statistics says the number of human beings without housing who died on the streets has increased b

drug maker pfizer and british multinational glaxo smith kline or g s k say they will merge their over the counter product units into a new corporate entity taking stakes of thirty two percent and sixty eight percent respectively in the new unit the company say the corporate coupling will yield six hundred thirty three million dollars or about five hundred million pounds of savings between the two companies g s k says the new unit and the remainder of their company will separate and stock listings within three years of the deals completion in late two thousand and nineteen stock prices for g s k n pfizer were up sharply in london and u.s. exchanges by more than seven and fourteen percent respectively on that. and the latest figures from the u.s. department of housing and urban development or hud indicate that homelessness has increased for the second year in a row hud's latest report estimates the u.s. homeless population at five hundred thirty three thousand in january twenty eighth seen with two thirds of those people lacking any form of shelter while the increase was small the trend

then, a former trump white house and pfizer and author will talk about the mueller investigation and his new book. be sure to watch c-span's "washington journal," live at 7:00 eastern sunday morning. join the discussion. ♪ -- aorida representative

drug maker pfizer and british multinational glaxo smith kline or g s k say they will merge their over the counter product units into a new corporate entity taking stakes of thirty two percent and sixty eight percent respectively in the new unit the company say the corporate coupling will yield six hundred thirty three million dollars or about five hundred million pounds of savings between the two companies g s k says the new unit and the remainder of their company will separate and stock listings within three years of the deals completion in late two thousand and nineteen stock prices for g s k n pfizer were up sharply in london and u.s. exchanges by more than seven and fourteen percent respectively on that. and the latest figures from the u.s. department of. housing or urban development or hud indicate that homelessness has increased for the second year in a row hud's latest report estimates the u.s. homeless population at five hundred thirty three thousand in january twenty eighth seen with two thirds of those people lacking any form of shelter while the increase was small the trend

gsk will have a 68% stake and pfizer 32%. glaxosmithkline's chief executive emma walmsley will chair the newjoint venture. two giants giving birth to a new baby, but a giant baby because this thing will have global sales of $13 billion. and the rationale for this is that this business is less risky, it has higher cash flows and by splitting it off you will get more. the parts will be worth more than some was before. the uncertainty over brexit is hitting the uk's employment situation and in particular creating a shortage among skilled drivers. the road haulage association says the industry is 55 to 60,000 drivers short and the workforce is rapidly ageing. the rha says it has as many of their members' drivers are eu citizens and most would not qualify as highly skilled under proposed immigration arrangements. let's talk to richard burnett, ceo of the road haulage association. thank you forjoining us. explain why there is such a skills shortage amongst drivers. the average age of amongst drivers. the average age of a driver is

mostraba heridas y cortes por todo su cuerpo en caleras, estómago, rodillas, glúteos, codos y la cabeza de pfizer liga estaba obligado a ducharse con ante la fiscalía acusa a leiva de torturar a rafael . >>> estamos viendo imágenes en vivo desde la rotonda en washington donde descansan los restos de bush padre. se despedirá al expresidente el próximo miércoles en lugar albergara lana: espera que aparezcan todos los expresidentes higos y la seguridad será extrema. >>> se transportó al féretro de bush padre hasta la capita del país. se llevó el presidente tr declaró días de duelo nacional. >>> las cámaras captaron el momento en que dos madres migrantes de la caravana se presentan al puerto de entrada para pedir asilo político. ellas estuvieron obedeciendo la ley vilar ninguna regla y frondas seguidas de una forma que no esperaban. >>> las madres migrantes de la caravana caminaron desde el albergue hasta el centro fronterizo su entrada fue negada. >>> de este modo agentes incluso las guardias le pedían alta cámaras abogo inmigración accionar las acciones de las va el ala fronteriza

pfizer, bristol, that'll get you done >> there you go. big cap pharma it was a wild year for the markets and an even wilder one here on "fast money. it's only proper that as 2018 draws to a close, we take a minute to look back at some of "fast money's" greatest moments of 2018. >> "fast money" starts right now live from the nasdaq market site overlooking new york's times square >> if you're looking downstream, if you look at every -- >> it's absurd >> put them up >> put them up >> you're wrong. >> i don't like your shirt, and i don't like your tie. i don't like you at all. >> are you unponytailed? this could be tv history >> actually, i am. i'll give you a little tease >> we got a smile out of dan today. [ cheers and applause nice job >> i think it makes for a good ceo and credibility, makes for little hearts and happy investors. >> come on over, carter. >> you didn't even put it up to a vote >> why should i? i'm in charge. carter comes over. carter come on over to the desk. come on over, carter dan's not coming over. >> fix this up a lit

with the talking about money a major merger in the pharmaceutical world that's right the giants pfizer and black so smith kline a forging an alliance that will be worth billions the two pharma companies plan on joining them over the counter productivity last year they had a combined turnover of almost thirteen billion dollars pfizer will hold on to so as the two percent of the plant join venture. will get sixty eight percent the next step will be to float the new company on the stock exchange. a little earlier i spoke to our markets goes one and only boss in frankfurt asking him if the two partners actually see eye eye to. yes and they have to see eye to eye to make it work you know we've seen so many mergers and bringing together of units in the past where when you get down to that it greatly the every day important decisions that are important to executives but also to the normal workers where there are differences differences in culture is an interest and then the thing goes sour so they have to work together but investors thinking this is a great idea the shares are going up pfizer

glaxo shares jumping as they announce a deal with pfizer. this is bloomberg. ♪ vonnie: live from new york, i am vonnie quinn. guy: in london, i am guy johnson. this is "bloomberg markets." taylor: all about the year ahead and joining me is rj gallows, senior portfolio manager at federated managers. as we look at 2018 and the year that was, barclays index, has had low positive returns. bank of america index has been slightly negative concerns. what has been your biggest concern for the market in this area? >> good morning and thank you for having me back. this year is the year of medium returns. the fed has tightened multiple times. it has been shrinking the balance sheets and that has become the headwind of financial assets -- assets of many stripes. that is theeturn instrument of investment. it's interesting risk asset volatility has not yet produced more demand for muni beautiful funds. people see cash as a real alternative. it gives a return roughly equal to inflation. that has been a challenge as we close out the year. taylor: how does

get off pfizer's all the seagull but situated. as if it was. supposed to be. going there all the same to me to sing hello to difficult such a. long. long long long long long song. most long. long long long the book. the long long long long long long long long long long long long long long long long. long long long long long long long cut the budget cut. the big. you're. in. the city as. a city hall he said. and let me. stay for the. at the time to get off on that call as for me. the call feels at. the end makes people. have to eat empathy and. really because. it's upset them complete. and it's a call. like the foxy little kid. shut the book. or something. if she. is good. looking young with. a coke call for to seke go see. which the funny and typically. the faithful. call. home that's their call and so we're. going to have to. let. you see feel. happy and people. would look. up to. looking for. cialis. oh. ok that's good. because. you know. you're. let me tell you mother. this is. the misfortune of. so sick. her point with. the beyondblue surely don't instantl

james comey's statements about the pfizer court and the role of the dossier are not true. james clapper lied under oath to congress, john brennan lied under oath to congress. susan rice lied when she said she did not request surveilled transcripts. we know that huma abedin lied. that's not even getting into the deception of the pfizer court or the way the investigations went on the email scandal, or putting informants in the presidential campaign. we had lots of wrongdoing by elites and there has been no consequences, so the american people are not paranoid, they are saying, the mueller investigation is going here but they are going after mr. mÉniÈre's or nothing. then finally, this mueller investigation is not in isolation. we had if you remember the day trump was elected, we were told that the voting machines were fraudulent. then you remember the electoral college, we had to overturn to the elect doors and then we went to the 25th amendment that trump was unbalanced. and then we have gone to muelle mueller. there's a slow-motion coup, and we do not want to destroy to

>> glaxo get the rhine share, 58% and pfizer get the rest. that is probably because they have the perspective of the ipo three years down the road. business andumer into that medicine business of vaccines and oncology. > in the midterm contributing relatively larger cash flows from this joint venture to continue to fund our number one priority which was the pipeline. we also give visibility to the eventual separation post-integration and as we have further progressed in our pharma pipeline that will allow us to reset the balance sheet. -- very much based on the science of immunology and onetics and new technology one new world leader in consumer health care. >>. 's>> souring the christmas season for retailers. they have lowered their 2019 sales outlook. it was lower at the open by 38%. given a sus was the retailer that was on it for so many years? >> they are blaming a few factors relate. the first one is consumer confidence has really slumped. not just in the u.k.. not just in france and germany. we introduced black friday in the u.k. and it

joint up over 7% after a venture with pfizer. sales will be worth more than 10 billion euros. insight into what the jobs of the future might be. been role --has mulling over the new roles that will emerge as artificial intelligence and other technology revolutionizes industry. some titles are terrifying, including chief purpose planner, cyber calamity forecaster and a flying car developer. the importance of re-skilling. >> i would like to be a flying car developer. it is now time for the press review. haveok at what the papers been saying. let's focus on the american press. michael flynn and what was expected to be a sentencing hearing over charges he lied to the fbi. a he went into this expecting light sentence and no jail time. he was rebuked for selling out his country. debate.ent is creating some papers are saying the judge went too far. the atlantic says the judge did tol, especially in regards their argument he was tricked into lying to the fbi. that he wasn disgusted by it proves politically effective arguments or political spin do not hold up in court. the paper is ref

consumer health units and that will help pfizer focus on consumer health. they should have separate capital structures, so this will help them do that. 4%.lilly is up almost they are predicting better than expected forecasts based on pharma sales and pushing back concerns.bout price i want to look at some of the other movers, ge is one up about 7%. they are expected to file their health unit ipo for global research analyst jeff sprague. it is upgrading this to a buy from a hold. most of the risks around ge are mostly pretty well understood, taking away the uncertainty. general mills up almost 7%. in april, they bought petfood blue buffalo. petfood is growing faster than human food, so that seems like a good acquisition. they are expanding that distribution -- the distribution of blue buffalo. overall, a pretty good day for general mills. david: thank you so much. trade talks between china and the united states to resume, but what progress can be made? bonnie chin will be joining us next. this is bloomberg. ♪ david: this is "balance of power." bmw andry ca

>> glaxo gets the lions share, 68% of the joint venture, pfizer gets the rest. investors are saying it is probably because they have that perspective of the ipo three years down the road. this is essentially a split up through the medicine business, vaccines and that kind of stuff. >> they are contributing significantly larger cash flows from the joint venture, continuing to fund on priority on the pharma pipeline, and we also give visibility to the eventual separation post integration, and as we've made further progress, that will allow us to reset the balance sheets of two companies to focus u.k. base, one pharma in vaccines, very much a on the science of immunology, and one new world leader in consumer health care. ? >> a profit warning from britain's aphis. it tumbled as it lowered its 2019 sales outlook, lower at the open by 38%. why is it suffering given that they were the retailer that was on it for so many years? >> that's right. they are claiming a few factors, the first is that consumer confidence has slumped, not just in the u.k. but also in france an

>> glaxo gets the lions share, 58% of the joint venture, pfizer gets the rest. investors are saying it is probably because they have that perspective of the ipo three years down the road. this is essentially a split up into the consumer business and the medicine business, vaccines and that kind of stuff. >> and the near term, we are contributing significantly larger cash flows from the joint venture, continuing to fund on priority on the pharma pipeline, and we also give visibility to the eventual separation post integration, and as we've made further progress, that will allow us to reset the balance sheets of two companies to focus u.k. base, one pharma in vaccines, very much a on the -- very much haste on the science of -- very much based on the science of immunology, and one new world leader in consumer health care. ♪ >> a profit warning from britain's aphis. it tumbled as it lowered its 2019 sales growth outlook lower , at the open by 38%. why is it suffering given that it was the retailer that was on it for so many years? >> that's right. they are claimin

james comey's statements about the pfizer court and the role of the dossier are not true. james clapper lied under oath to congress, john brennan lied under oath to congress. susan rice lied when she said she did not request surveilled transcripts. we know that huma abedin lied. they said they did not have knowledge of the email server of their boss, hillary clinton. that's not even getting into the deception of the pfizer court or the way the investigations went on the email scandal, or putting informants in the presidential campaign.f we had lots of wrongdoing by elites and there has been no consequences, so the american people are not paranoid, they are saying, the mueller investigation is going here but they are going after misdemeanors or nothing. then finally, this mueller investigation is not in isolation.meg we had if you remember the day trump was elected, we were told that the voting machines were fraudulent. then you remember the electoral college, we had to overturn to the elect and then we went to the 25th amendment that trump was unbalanced. and then we have

emma walmsley has launched a plan to split the group in two and launch a joint venture with us rival pfizer — creating the world's largest provider of over—the counter drugs. and finally, ‘grey rage‘ leads the daily mirror, after calls from the royle family star ricky tomlinson for a pensioners‘ revolt to protect free tv licences. we are going to start off, kate and david comeau with the telegraph. it's 100 david comeau with the telegraph. it‘s 100 days officially. should we start... talk us through this. it‘s 100 days officially. should we start... talk us through thislj think start... talk us through this.” think it‘s good that christmas is coming up. everyone needs to take a deep breath. go home and reboot. it doesn‘t matter which side of the policy debate you‘re on. i think eve ryo ne policy debate you‘re on. i think everyone is getting very close to losing their minds as they operate politically with each other. the government has not helped. protocols have gone out the window. there was going to be a meaningful vote. they promised it.

>> glaxo gets the lions share, 68% of the joint venture, pfizer gets the rest. investors are saying it is probably because they have that perspective of the ipo three years down the road. this is essentially a split up through the medicine business, vaccines and that kind of stuff. >> they are contributing significantly larger cash flows from the joint venture, continuing to fund on priority on the pharma pipeline, and we also give visibility to the eventual separation post integration, and as we've made further progress, that will allow us to reset the balance sheets of two companies to focus u.k. base, one pharma in vaccines, very much a on the science of immunology, and one new world leader in consumer health care. ♪ >> a profit warning from britain's aphis. it tumbled as it lowered its 2019 sales outlook, lower at the open by 38%. why is it suffering given that they were the retailer that was on it for so many years? >> that's right. they are claiming a few factors, the first is that consumer confidence has slumped, not just in the u.k. but also in france

they cannot find any substantial facts to substantiate what was presented to the pfizer court, not just the reporters from "the washington post," we had bob woodward writing books and other reporters doing deep investigative work into this and nobody can substantiate it. step aside from the reporters for a moment, what about what the reporters admitted? they cannot substantiate what is in the dossier and still people are operating under the assumption especially with the special counsel that there was something there to be investigated. >> and then after two years there has been absolutely no evidence connecting this administration, this president, or anyone with any russia collusion. or i call it, delusion. >> think about where we are right now. everything monica just said is absolutely accurate. despite mounds of resources, international intelligence operations trying to verify to the press that this dossier appears to be one big hoax. but here's the problem. the investigation into donald trump, judge, would not exist without the dossier. don't take my word for it. i get it, the anti-

fritto lewis hall from pfizer. and rachel holt from uber. and we're going to delve into what is working around the world, to foster the rise of women leaders, what things companies are doing and changing, and i'm going to ask these women for take-aways from their own play books that we can use, maybe as soon as tomorrow, you know, to kick off some of these powerful roles that we are trying to achieve. we want to hear from you. so please use the hash tag rule with us on twitter, so we can ask your questions of our panelists as well. and i will dive right into here, starting with freeda. is there something that we as women are doing to keep ourselves from positionis of power? >> i would probably turn that question around just a little bit. just a little bit. because i am worried about something. and that is, you know, we talk a lot about personalized medicine and personalized this and permized that and i'm not sure that we really are personalizing our career development and advancement. and by that, i mean different cultures, different functio

a british drugmaker and pfizer have agreed to a joint venture. brands include sense of thine -- sensodine. later, we will speak to the ceo of glaxosmithkleine. tom: there is an an incredible amount of stuff out there right now. rita is with us. with all of the analysis i have about andill talk -- davidd citigroup shepard today in the financial times absolutely kills it with a data laden summary of where we are. i don't think most of the world understands what u.s. oil is doing. u.s. shale juggernaut russia. the u.s. oil production increase in 2018 is roughly equivalent to oil output of iran's to the market in one year. and the united states, is larger than the individual output of 8 of opec's 14 members. how is the u.s. going to drive oil in 2019? are we going back to $30 a barrel? >> if we continue at these kind of levels, the one thing i would add is the 2 million barrels of growth wasn't a problem when demand growth was very strong. it is becoming a problem now because demand is slowing. i think we should always put that in context. if it cont

pfizer has a business they don't want so they said let's combine it as a joint venture and maybe spin it out sometime in the next few years. >> david, we're going to leave it there thank you very much. >>> paul ryan and kevin mccarthy speaking outside the white house moments ago. let's take a listen. >> all right let me just start off right now, we just had a very long productive meeting with the president. the president informed us that he will not sign the bill that came over from the senate last evening because of his legitimate concerns for border security so what we're going to do is go back to the house and work with our members, we want to keep the government open but we also want to see an agreement that protects the border. we have very serious concerns about securing our border, so the president said he will not sign this bill, so we're going to go back and work on adding border security to this, also keeping the government open because we do want to seen a agreement. >> we believe there's still time, we could have border security, fundamentally that's what america is asking

now for a call on a current dow component, pfizer. jpmorgan chase cutting fiz tore ne pfizer to neutral from overweight the valuation is no longer attractive their target remains 46. now to the news out of the c suite. if a company does not innovate it could die that was the topic of last night's cnbc net-net event this is what johnson & johnson's chairman told a room of business leaders. >> one scheme we have honed over time is partner with innovators. that's one of the most important ways we remain innovating is partnering with others that have important innovations and that can make an impact >> for more go to cnbc.com/net-net don't do it now if you're driving. >>> frank holland is back with trending stories what's trending? >> we have some good up withes today. >> thank goodness you don't have bad ones today that's a win >> delta air lines announcing major changes to rules about pets on flights. emotional support animals will not be allowed on flights longer than eight hours it is barring animals younger than four months old from

is such that when you have a drug on the market that's cheaper, i mean, look two of your competitors pfizer announced this week they are merging consumer system divisions, is that a bay to get prices in a better state where you actually see companies coming together? >> maybe, that's a combination for over the counter medications, the ones you buy off the shelfs in walgreens or cvs. maria: if you need a prescription and you're sick, you need a prescription for a cancer medication, you're talking about $150,000 a year. >> in some cases those -- those are the costs, that's because r r&d is expensive and the way economics work they are paying r&d for next cancer medications, the real issue is out of pocket costs, we are for change in that model. patients are paying too much out of pocket costs. so the administration proposed a number of ways to get at this including narrowing the spread between the list price and the net pricing and we think some of those are good ideas whether it would be passing through rebates that your insurance companies negotiates on your behalf. today they negotiate reb

as soon as this volatility stabilizes a bit but this would be my pick among stocks like pfizer, lilly, merck, abbott labs they offer relative safety and a bit more stability than you see in technology for sure final chart look at the s&p. so we have seen this break really in the last couple of days and unfortunately, you know, s&p has formed a pretty decent topping formation that started back in january. one thing i want to point out, everybody is saying momentum is oversold it has gotten oversold on a daily basis. however weekly basis we are not nearly at levels we saw back in 2008, 2009 on a monthly basis s&p really got oversold and we are no where near that also it's on a daily basis only that s&p has gotten to oversold levels we only see 2% of all stocks above the 10-day moving average. my thinking is this decline this put back to 2376 peace a 50% retracement since 2016 there are a couple of short term cycles now past fomc sentiment will turn bearish more quickly. people think there is no catalyst to lift the market. if anything you want to look for a day like tomorrow on quad whi

pharmaceutical giant pfizer and glaxo smith kline are forging an alliance that will be worth billions they plan on joining their over the counter product divisions last year they had a combined turnover of almost thirteen billion dollars glaxo will hold about two thirds of the cloud to join venture pfizer will get the rest the next step will be to float the company on the stock exchange. of more business coming up for you later in the show for now back to late and a sad anniversary here in the german capital right christoph berlin is marking the second anniversary of the terror attack that left twelve people dead and dozens injured in the german capital family and friends of victims joined berlin's mayor and other officials at a ceremony at the site of the attack exactly two years ago i rejected asylum seekers from tunisia named in the hijacked a truck killed its driver and plowed into a crowd at christmas market and we escaped but was shot dead by police in the a few days later. while we met a survivor of the attack whose life has not been the same ever since. i think. as i turned ar

pfizer used to shavings i. saw your come on you know now we can add some raisins on the glacier we put in raisins but you can leave them out if you wish. that. we sell up to four tons of man in the winter season that's one hundred fifty to two hundred portions a day. kaiser should be baked for five minutes on each side and then it's ready. stephany's i'm too low also supply. the restaurant's week. and clips. is said to get its name from a pancake that went wrong. the austrian emperor of france use it. but when a pancake fell apart during cooking people scrambled up and served. the emperor loved it and then purse crumbled all kinds of smart. so now it's just missing the icing sugar on top you know here we serve our kaiser with apple sauce and thing on their. mind isn't just a favorite thing to roll it's one of austria's most popular designs. and finally before we go we want to let you win on the winner of this week's draw we asked you to send us a photo of your best moment of two thousand and eighteen and we rec